Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Colin Baigent,Lisa Blackwell,Rory Collins,Jonathan Emberson,Jon Godwin,Richard Peto,Julie E. Buring,Charles H. Hennekens,Patricia M. Kearney,Tom W. Meade,Carlo Patrono,Maria Carla Roncaglioni,Alberto Zanchetti +12 more
Reads0
Chats0
TLDR
In primary prevention without previous disease, aspirin is of uncertain net value as the reduction in occlusive events needs to be weighed against any increase in major bleeds.About:
This article is published in The Lancet.The article was published on 2009-05-30 and is currently open access. It has received 2954 citations till now. The article focuses on the topics: Stroke & Aspirin.read more
Citations
More filters
Journal ArticleDOI
Cost-effectiveness of a fixed-dose combination pill for secondary prevention of cardiovascular disease in China, India, Mexico, Nigeria, and South Africa: a modelling study.
John K Lin,John K Lin,John K Lin,Andrew E. Moran,Kirsten Bibbins-Domingo,Bode Falase,Andrea Pedroza Tobias,Charuta N Mandke,Dhruv S. Kazi,Dhruv S. Kazi +9 more
TL;DR: The polypill is projected to be cost-effective compared with current care for secondary prevention of atherosclerotic cardiovascular disease in China, India, Mexico, Nigeria, and South Africa, particularly if it is made available at public-sector pricing.
Journal ArticleDOI
Aspirin resistance, platelet turnover, and diabetic angiopathy: a 2011 update.
Matteo Nicola Dario Di Minno,Roberta Lupoli,Nicola Macarone Palmieri,Anna Russolillo,Agostino Buonauro,Giovanni Di Minno +5 more
TL;DR: As many as 25years after its original publication, the clinical relevance of an accelerated platelet turnover as to "aspirin resistance" has been confirmed and extended to other clinical settings at high risk of ischemic events.
Journal ArticleDOI
Slowing the progression of age-related hearing loss: Rationale and study design of the ASPIRIN in HEARING, retinal vessels imaging and neurocognition in older generations (ASPREE-HEARING) trial
Judy Lowthian,Carlene Britt,Gary Rance,F.R. Lin,Robyn L. Woods,Rory Wolfe,Mark Nelson,Harvey Dillon,Stephanie A. Ward,Christopher M. Reid,Jessica E. Lockery,Thanh T. Nguyen,John J McNeil,Elsdon Storey +13 more
TL;DR: This study aims to determine whether low-dose aspirin decreases the progression of ARHL, and if so, whether this decrease is also associated with retinal microvascular changes and/or greater preservation of cognitive function.
Journal ArticleDOI
Statins and Aspirin for Chemoprevention in Barrett's Esophagus: Results of a Cost-Effectiveness Analysis
TL;DR: Aspirin chemoprevention was both more effective and cost less than endoscopic surveillance alone and combination therapy using both aspirin and statin could be cost-effective in patients at higher risk of progression to esophageal adenocarcinoma.
Journal ArticleDOI
Lipid Association of India (LAI) expert consensus statement on management of dyslipidaemia in Indians 2017: part 2
S S Iyengar,Raman Puri,S. N. Narasingan,Devaki Nair,Vimal Mehta,Jagdish C. Mohan,Subhash Kumar Wangnoo,J. J. Dalal,V. Jha,S. Puri,Anoop Misra,Mradul Kumar Daga,M. S. K. Varma,Sanjiv Jasuja,S. D. Upadhyaya,Ravi R Kasliwal,Manish Bansal,Rahul Mehrotra,A. Jain,Kewal K. Talwar,Rajesh Rajput,Akshyaya Pradhan,Shashi Seth,Dheeraj Kapoor,R. P. Melinkeri,Sivasubramanian Ramakrishnan,Narendra N. Khanna,Rajesh Khadgawat,Altamash Shaikh,N. Kovalipati,N. Bordoloi,Abdul Hamid Zargar,Rajeev Agarwal,Ashu Rastogi,M. Chag,D Prabhakar,S. K. Mathur,Harmeet Singh Rehan,P. K. Sahoo,A.L. Dutta,A. D. Sharma,A. K. Pancholia,K. U. Natarajan,A. Mishra,K. K. Singh +44 more
TL;DR: These Lipid Association of India (LAI) recommendations refer to specific patient populations, including patients with heart failure, chronic kidney disease, non-alcoholic fatty liver disease, cerebrovascular disease, thyroid disorders, inflammatory joint diseases, familial hypercholesterolaemia and human immunodeficiency virus infection.
References
More filters
Journal ArticleDOI
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
Colin Baigent,Anthony C Keech,Patricia M. Kearney,L Blackwell,Georgina Buck,Christine Pollicino,Adrienne Kirby,T Sourjina,Richard Peto,Rory Collins,R. J. Simes +10 more
TL;DR: Statin therapy can safely reduce the 5-year incidence of major coronary events, coronary revascularisation, and stroke by about one fifth per mmol/L reduction in LDL cholesterol, largely irrespective of the initial lipid profile or other presenting characteristics.
Journal ArticleDOI
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
TL;DR: Aspirin (or another oral antiplatelet drug) is protective in most types of patient at increased risk of occlusive vascular events, including those with an acute myocardial infarction or ischaemic stroke, unstable or stable angina, previous myocardian infarctions, stroke or cerebral ischaemia, peripheral arterial disease, or atrial fibrillation.
Journal ArticleDOI
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial
Lennart Hansson,Alberto Zanchetti,S. George Carruthers,Björn Dahlöf,Dag Elmfeldt,Stevo Julius,Joël Ménard,Karl Heinz Rahn,Hans Wedel,Sten Westerling +9 more
TL;DR: Intensive lowering of blood pressure in patients with hypertension was associated with a low rate of cardiovascular events and the potential benefit of a low dose of acetylsalicylic acid in the treatment of hypertension was assessed.
Journal ArticleDOI
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Paul M. Ridker,Eleanor Danielson,Jacques Genest,Antonio M. Gotto,Wolfgang Koenig,Peter Libby,Alberto J. Lorenzatti,Jean G. MacFadyen,Børge G. Nordestgaard,James Shepherd,James T. Willerson,Robert J. Glynn +11 more
TL;DR: In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.
Journal ArticleDOI
Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies
Gary Whitlock,Sarah Lewington,Paul Sherliker,Robert Clarke,Jonathan Emberson,Jim Halsey,Nawab Qizilbash,Rory Collins,Richard Peto +8 more
TL;DR: Below the range 22.5-25 kg/m(2), BMI was associated inversely with overall mortality, mainly because of strong inverse associations with respiratory disease and lung cancer, despite cigarette consumption per smoker varying little with BMI.